Login to Your Account

Basilea Falls as FDA Delays Ceftobiprole Decision Again

By Catherine Hollingsworth and Cormac Sheridan

Monday, December 1, 2008
The FDA again delayed its review of cephalosporin antibiotic ceftobiprole due to unresolved "data integrity issues," an unexpected setback for Swiss biotech Basilea Pharmaceutica Ltd. and co-development partner Johnson & Johnson Pharmaceutical Research & Development LLC. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription